

ASX RELEASE

25 August 2022

CEO & Managing Director's Presentation to Annual General Meeting

Amplia Therapeutics Limited (ASX: ATX) ("Amplia" or the "Company") is pleased to release the CEO & Managing Director's presentation to the Company's Annual General Meeting (YE 31 March 2022) to be held today.

This ASX announcement is authorised for release by the Company Secretary.

- End -

For Further Information

Dr. John Lambert
Chief Executive Officer
john@ampliatx.com
www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).



ampliatx.com

Annual General Meeting

25 August 2022



Disclaimer

The information contained in the presentation is not intended to be an offer for subscription, invitation or recommendation with respect to shares of Amplia Therapeutics Limited (“Amplia”) in any jurisdiction. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained in this document or opinions expressed in the course of this presentation. The information contained in this presentation is subject to change without notification.

This presentation contains forward-looking statements which can be identified by the use of words such as “may”, “should”, “will”, “expect”, “anticipate”, “believe”, “estimate”, “intend”, “scheduled” or “continue” or similar expressions. Any forward-looking statements contained in this presentation are subject to significant risks, uncertainties, assumptions, contingencies and other factors (many of which are outside the control of, and unknown to Amplia, and its officers, employees, agents or associates), which may cause the actual results or performance to be materially different from any future result so performed, expressed or implied by such forward-looking statements.

There can be no assurance or guarantee that actual outcomes will not differ materially from these statements. The data and results pertaining to clinical subjects used in this presentation are illustrative of medical conditions and outcomes associated with potential applications of Amplia’s acquired product pipeline. Actual results from clinical trials may vary from those shown.

Agenda



- 1 Company overview and the year in review
- 2 Technology
- 3 ACCENT trial - 1st line pancreatic cancer
- 4 Plans for FY2023

Company and Year in Review



Our values

- Patients first
- Integrity
- Respect
- Performance
- Innovation
- Accountability
- Excellence



Our people



Rhiannon Jones
Chief Operating Officer



Terrie-Anne Cock
Head of Translational Biology



Anthony Bishop
Principal Development Manager



Charlotte Mulder
Principal Development Manager



Nicole Kruger
Clinical Operations Manager



Adrian Sulistio
CMC Project Manager



Hamish George
Chief Financial Officer




Andrew Cooke
Company Secretary

Amplia's year in review | Focus areas

- Establishment of AMP945 clinical trial in patients with pancreatic cancer - ACCENT
- Toxicology studies in preparation for extended dosing of AMP945 in patients with pulmonary fibrosis
- Improvement of AMP945 manufacturing methods in readiness for commercialisation
- Validating our AMP945 development plans with US FDA
- Surveying the opportunity landscape for AMP886 and AMP945
- Building the right team to deliver objectives

Cash position



Cash burn rate will be substantially driven by rate of recruitment into ACCENT trial


R&D Tax Rebates forecast as income in FY2022 and FY2023

* Amplia Therapeutics 2022 Annual Report


** Amplia Therapeutics July 2022 Appendix 4C

Capital efficiency

FY22 expenditure | \$5.63m




Amplia's year in review | Outcomes



A photograph of a scientist in a white lab coat, safety glasses, and a face mask, looking through a microscope. The image is overlaid with a semi-transparent cyan filter. The scientist's hands are wearing white gloves. The background is a blurred laboratory setting.

Technology




- Developing inhibitors of Focal Adhesion Kinase (FAK)
 - Small molecule
 - Orally bioavailable
 - Potent and selective
- Indications
 - Oncology
 - Fibrosis
- Clinical stage
 - First-line advanced pancreatic cancer
 - Pulmonary fibrosis

Amplia's drug target | Focal adhesion kinase



Fibrotic Tissue

Fibrosis:
Collagen deposition
Collagen crosslinking



Focal Adhesion Kinase (FAK)


Fibrosis
Immunosuppression



Fibrotic tumour microenvironment




Fibrotic Diseases




Solid Cancers

Amplia's pipeline



Current Status




Next 12-months

Drug	Indication	Therapy	Preclinical	Phase 1	Phase 2	Phase 3 (approval)
AMP945	Pancreatic Cancer	Combination Therapy				
AMP945	Idiopathic pulmonary fibrosis (IPF)	Monotherapy				
AMP945	Cancers & fibrotic disease	Combo/ Monotherapies				
AMP886	Cancers & fibrotic disease	Combo/ Monotherapy				




Amplia's hypothesis | Enhancing chemotherapy

- Fibrotic shields protect many solid tumours from chemotherapy
- Amplia's FAK inhibitors aim to remove the shield
- Unshielded tumours should be more susceptible to chemotherapy



AMP945 improves survival in pancreatic cancer models




KPC Model

- Vehicle
- gemcitabine / nab-paclitaxel
- AMP945 / gemcitabine / nab-paclitaxel

$P \leq 0.001$

$P \leq 0.05$




TKCC-10-LO Orthotopic Model

- Vehicle
- gemcitabine / nab-paclitaxel
- AMP945 / gemcitabine / nab-paclitaxel

$P \leq 0.0001$

$P \leq 0.05$

Amplia's hypothesis | Treating fibrosis




- Idiopathic pulmonary fibrosis (IPF) is a dangerous progressive disease with poor treatment options
- FAK plays a key role in establishment of fibrotic tissue
- Preclinical studies in models of lung fibrosis show that AMP945 reduces lung fibrosis
- AMP945's clinical safety profile appears excellent
- Safety profile and disease model data provide rationale for testing in IPF

AMP945 inhibits fibrosis

Total collagen decreases ●.....●



Cross-linked collagen decreases ●.....●



- Cross-linked collagen is a key component of fibrotic tissues


- AMP945 inhibits collagen formation and collagen cross-linking in a dose-dependent manner



AMP945 Clinical Development

ACCENT:
Proof of Concept Trial in
First Line Pancreatic
Cancer Patients

ACCENT: Clinical study of AMP945 in people with pancreatic cancer



First-line patients with advanced pancreatic cancer

- Open label
- AMP945 added to gemcitabine/nab-paclitaxel standard of care
- Not previously treated with gemcitabine and/or nab-paclitaxel
- Primary endpoint: Objective Response

One protocol, three stages

Part A - Dose confirmation (~12 patients)

Part B: Stage 1 - exploratory efficacy (26 patients)

Part B: Stage 2 - verification of efficacy (24 patients)

ClinicalTrials.gov Identifier: [NCT05355298](https://clinicaltrials.gov/ct2/show/study/NCT05355298)

ACCENT trial startup



HREC 1 (NSW) April '22
HREC 2 (Victoria) May '22

Contract negotiations

Site Initiation Visits (SIV)


Recruit

- Initial Company forecasts were for recruitment to commence in CQ1 2022
- Following HREC approvals, site contract discussions were straightforward but slower than forecast
- Knock-on effect to SIVs and Recruitment
- First patient recruited August 2022


Tactics to optimise recruitment

- Add more sites in AU - minimise risk of recruitment bottleneck for both Parts A and B
- Media campaign
- Korean startup - reputation as high quality recruiters

ACCENT | Regulatory and recruitment strategy



ACCENT | Recruitment forecast



Australia (4-8 sites)




South Korea (5 sites)



USA (# sites TBD)

ACCENT | Decision points



Australia (4-8 sites)




South Korea (5 sites)




USA (# sites TBD)

ACCENT | Australian sites

- Follow on sites - Part B and Part A contingency
- Recruiting



ACCENT | Part A, dose escalation



Outcomes

- Safety and tolerability in target population who are also receiving chemotherapy
- Efficacy assessments
- Dose selection for Part B

Plans for FY2023

Value drivers



Clinical milestones

- Pancreatic cancer ●.....● ACCENT results
- Pulmonary fibrosis trial



Regulatory engagement

- US and Korean INDs



Expand therapeutic opportunities for AMP945

- Cancer
- Fibrosis



Expand pipeline by progression of AMP886



Thank You.

Amplia Therapeutics Limited

ABN 16 165 160 841

ASX: ATX

info@ampliatx.com

ampliatx.com

Dr John Lambert
Chief Executive Officer
john@ampliatx.com

